
... BIBLIOGRAPHY ...

- American Diabetes Association. Consensus Statement: Role of cardiovascular risk factors in prevention and treatment of microvascular disease in diabetes. *Diabetes Care* 1989;12:573-579.
- American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997;20:1183-1197.
- American Diabetes Association. Standards of medical care for patients with diabetes mellitus. *Diabetes Care* 1997;20(Suppl):S5-S17.
- American Heart Association. 1997 *Heart and Stroke Statistical Update*. Dallas, TX: American Heart Association, 1996.
- Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. *N Engl J Med* 1995;332:488-493.
- Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. *Circulation* 1997;95:324-328.
- Aronow WS, Ahn C. Correlation of serum lipids with the presence or absence of coronary artery disease in 1793 men and women aged ≥ 62 years. *Am J Cardiol* 1994;73:702-703.
- Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. *Am J Cardiol* 1996;78:409-414.
- Assman G, Schulte H. Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease: The PRO-CAM experience. *Am J Cardiol* 1992;70:733-737.
- Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events: Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study (CLAS). *Circulation* 1996;93:34-41.
- Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. *JAMA* 1996;275:128-133.
- Ballantyne CM, Herd JA, Farmer JA, Jones PH, West MS, Gotto AM Jr. Cholesterol lowering to NCEP goal: The Lipoprotein and Coronary Atherosclerosis Study (LCAS). Presented at Biomedicine '97, Washington DC, April 26, 1997.
- Ballantyne CM, Herd JA, West MS, et al. Influence of low HDL-C on progression of CAD and response to fluvastatin therapy [abstract]. *J Am Coll Cardiol* 1997;29:232A.
- Baron AD. Insulin and the vasculature—old actors, new roles. *J Investig Med* 1996;44:406-412.
- Becker C. Hypothyroidism and atherosclerotic heart disease: Pathogenesis, medical management, and the role of coronary artery bypass surgery. *Endocrine Reviews* 1985;6:432-440.
- Bjorntorp P. The android woman—A risk condition. *J Intern Med* 1996;239:105-110.
- Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Axen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. *JAMA* 1987;257:3233-3240.
- Blumgart HL, Levine SA, Berlin DD. Congestive heart failure and angina pectoris: The therapeutic effect of thyroidectomy on patients without clinical or pathological evidence of thyroid toxicity. *Arch Intern Med* 1933;51:866-877.
- Brands MW, Hopkins TE. Poor glycemic control induces hypertension in diabetes mellitus. *Hypertension* 1996;27(Part 2):735-739.
- Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. *Circulation* 1993;87:1781-1791.
- Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med* 1990;323:1289-1298.
- Brown MS, Kovanen PT, Goldstein JL. Regulation of plasma cholesterol by lipoprotein receptors. *Science* 1981;212:628-635.
- Buchwald H, Matts JP, Fitch LL, et al, for the Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. Changes in sequential coronary arteriograms and subsequent coronary events. *JAMA* 1992;268:1429-1433.
- Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). *N Engl J Med* 1990;323:946-955.
- Burt VL, Whelton P, Rocella EJ, et al. Prevalence of hypertension in the US adult population: Results from the Third National Health and Examination Survey (NHANES III), 1981 to 1991. *Hypertension* 1995;25:305-313.

... BIBLIOGRAPHY ...

- Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in Coronary Drug Project patients: Long-term benefit with niacin. *J Am Coll Cardiol* 1986;8:1245-1255.
- Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. *Diabetes* 1996;45:633-638.
- Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. *J Intern Med* 1989; 226:271-276.
- Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. *Acta Med Scand* 1988;223:405-418.
- Castelli WP. Epidemiology of coronary heart disease: The Framingham Study. *Am J Med* 1984;76:4-12.
- Castelli WP. Lipids, risk factors and ischemic heart disease. *Artherosclerosis* 1996;124(Suppl):S1-S9.
- Collins P, Rosano GMC, Sarrel PM, et al. Seventeen B-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. *Circulation* 1995;92:24-30.
- Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. *JAMA* 1975;231:360-381.
- Curham GC, Willet WC, Rimm EB, Spiegelman D, Ascherio AL, Stampfer MJ. Birth weight and adult hypertension, diabetes mellitus, and obesity in US men. *Circulation* 1996;94:3246-3250.
- Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. *Am J Cardiol* 1997;79:38-42.
- Delp MD. Effects of exercise training on endothelium-dependent peripheral vascular responsiveness. *Med Sci Sports Exerc* 1995;27:1152-1157.
- Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977-986.
- Donohue RP, Orchard TJ. Diabetes mellitus and vascular complications: An epidemiological perspective. *Diabetes Care* 1992;15:1141-1155.
- Drood JM, Zinetbaum PJ, Frishman WH. Nicotinic acid for the treatment of hyperlipoproteinemia. *J Clin Pharmacol* 1991;31:641-650.
- Duflo J, Virmani R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. *Am Heart J* 1995;130:306-313.
- Dunaif A, Finegood DT. B-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. *J Clin Endocrinol Metab* 1996;81:942-947.
- EAS Study Group. Strategies for the prevention of coronary artery disease: A policy statement of the European Atherosclerosis Society. *Eur Heart J* 1987;8:77-88.
- Edson JR, Fecher DR, Doe RP. Low platelet adhesiveness and other hemostatic abnormalities in hypothyroidism. *Ann Intern Med* 1975;82:342-346.
- Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: Mechanisms of action on bile acid and cholesterol metabolism. *Eur J Clin Pharmacol* 1991;40(Suppl 1):S53-S58.
- Eisenberg JM. Clinical economics: A guide to economic analysis of clinical practices. *JAMA* 1989;262:2879-2886.
- Epstein RS, Garrahan S, Nelsen L, et al. The cholesterol population model: US population requirements for treatment of hypercholesterolemia. *Am J Man Care* 1996;2: 1362-1370.
- Falk E. Why do plaques rupture? *Circulation* 1992;86 (Suppl III):30-42.
- Forti N, Diogo Giannini D, Diament J, et al. Coronary risk factors in children of young coronary artery disease patients. *Arq Bras Cardiol* 1996;66:119-123.
- Frick MH, Elo MO, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. *N Engl J Med* 1987;317:1237-1245.
- Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med* 1992;326:310-318.
- Fu CC, Chang CJ, Tseng CH, et al. Development of macrovascular disease in NIDDM patients in northern Taiwan: A four-year follow-up study. *Diabetes Care* 1993;16:137-143.
- Gardner SF, Schneider EF, Granberry MC, Carter IR. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. *Pharmacotherapy* 1996;16:419-423.

... BIBLIOGRAPHY ...

- Garnett WR. A review of current clinical findings with fluvastatin. *Am J Cardiol* 1996;78(Suppl 6A):20-25.
- Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. *Am J Health Syst Pharm* 1995;52:1639-1645.
- Garnett WR. The pharmacology of fluvastatin, a new HMG-CoA reductase inhibitor. *Clin Cardiol* 1994;17:(Suppl IV):3-10
- Geurian KL. The cholesterol controversy. *Ann Pharmacother* 1996;30:495-500.
- Giles WH, Anda RF, Jones DH, Serdula MK, Merritt RK, DeStefano F. Recent trends in the identification and treatment of high blood cholesterol by physicians: Progress and missed opportunities. *JAMA* 1993;269:1133-1138.
- Gleuck CJ, Oakes N, Speirs J, Tracy T, Lang J. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. *Am J Cardiol* 1992;70:1-9.
- Goldman L, Garber AM, Grover SA, Hlatky MA. Task Force 6. Cost effectiveness of assessment and management of risk factors. *J Am Coll Cardiol* 1996;27:1020-1030.
- Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. *JAMA* 1991;265:1145-1151.
- Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. *Circulation* 1989;79:8-15.
- Gotto AM Jr. Lipid lowering, regression, and coronary events: A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention. *Circulation* 1995;92:646-656.
- Gotto AM, Gorry GA, Thompson JR, et al. Relationship between plasma lipid concentrations and coronary artery disease in 496 patients. *Circulation* 1977;56:875-883.
- Grossman E, Messerli FH. Diabetic and hypertensive heart disease. *Ann Intern Med* 1996;125:304-310.
- Grundy SM, Balady GJ, Criqui MH, et al. When to start cholesterol-lowering therapy in patients with coronary heart disease: A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. *Circulation* 1997;95:1683-1685.
- Grundy SM, Chait A, Clark LT, et al, for the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP). *JAMA* 1993;269:3015-3023.
- Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. *J Lipid Res* 1981;22:24-36.
- Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of increasing HDL-C. *JAMA* 1995;273:1032-1038.
- Hamman A, Flier JS, Lowell BB. Decreased brown fat markedly enhances susceptibility to diet-induced obesity, diabetes, and hyperlipidemia. *Endocrinology* 1996;137:21-29.
- Harris ME. Impaired glucose tolerance in the US population. *Diabetes Care* 1989;12:464-474.
- Haskell WL, Adelman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: The Stanford Coronary Risk Intervention Project (SCRIP). *Circulation* 1994;89:975-990.
- Herd JA, Ballantyne CM, Farmer JA, et al, for the LCAS Investigators. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). *Am J Cardiol* 1997;80:278-286.
- Herd JA, West MS, Ballantyne CM, et al. Beneficial effects of fluvastatin on clinical cardiac and all fatal events in patients with mild cholesterol elevations [abstract]. *J Invest Med* 1997;45:222A.
- Herd JA, West MS, Ferlic L, et al. Influence of age and sex on angiographic change in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) [abstract]. *J Am Coll Cardiol* 1997;29:139A.
- Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. *Am J Cardiol* 1994;73:951-952.
- Hjermann I, Holme I, Leren P. Oslo Study Diet and Antismoking Trial: Results after 102 months. *Am J Med* 1986;80(Suppl 2A):7-11.
- Holme I, Solberg LA, Weissfeldt L, et al. Coronary risk factors and their pathway of activation through coronary raised lesions, coronary stenosis and coronary death: Multivariate statistical analysis of an autopsy series: The Oslo Study. *Am J Cardiol* 1985;55:40-47.
- Houston-Miller N, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: Recommendations for a call to action. *Circulation* 1997;95:1085-1090.
- Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibi-

- tor monotherapy in the treatment of primary hypercholesterolemia. *Ann Pharmacol* 1995;29:743-759.
- Isles CG, Hole DJ, Gillis CR, Hawthorne VM, Lever AF. Plasma cholesterol, coronary heart disease, and cancer in Renfrew and Paisley survey. *Br Med J* 1989;298:920-924.
 - Jackson G. Risk factor management: The cardiologist's perspective. *Br J Clin Pract Symp* 1996;77(Suppl A):33-39.
 - Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: A preliminary report on safety. *Am J Cardiol* 1994;73:25D-29D.
 - Jacobson TA. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. *Am J Cardiol* 1996;78(Suppl 6A):32-41.
 - Johanneson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H, for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. *N Engl J Med* 1997;336:332-336.
 - Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V). *Arch Intern Med* 1993;153:154-164.
 - Jones PH. A clinical overview of dyslipidemias: Treatment strategies. *Am J Med* 1992;93:187-198.
 - Kagan A, Harris BR, Winkelstein W Jr, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: Demographic, physical, dietary and biochemical characteristics. *J Chronic Dis* 1974;27:345-364.
 - Kahle EB, Zipf WB, Lamb DR, Horswill CA, Ward KM. Association between mild, routine exercise and improved insulin dynamics and glucose control in obese adolescents. *Int J Sports Med* 1996;17:1-6.
 - Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham study. *Ann Intern Med* 1971;74:1-12.
 - Kannel WB, Gordon T, Schwartz MD, et al. Systolic versus diastolic blood pressure and risk of coronary heart disease: The Framingham study. *Am J Cardiol* 1971;27:335-346.
 - Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. *Am J Cardiol* 1995;76:69C-77C.
 - Karlsberg RP, Friscia DA, Aronow WS, Sekhon SS. Deleterious influence of hypothyroidism on evolving myocardial infarction in conscious dogs. *J Clin Investig* 1981; 67:1024-1034.
 - Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation: A pilot study. *Transplantation* 1996;61: 1469-1474.
 - Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin dependent diabetes. In: *Diabetes in America*. 2nd ed. National Diabetes Data Group, eds. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995:47-68. (NIH Publication No 95-1468.)
 - Keys A. Coronary heart disease in seven countries. American Heart Association Monograph #29 *Circulation* 1970;41(Suppl 1):1
 - Kinosian BP, Eisenberg JM. Cutting into cholesterol: Cost-effective alternatives for treating hypercholesterolemia. *JAMA* 1988;259:2249-2254.
 - Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. *N Engl J Med* 1993;328:313-318.
 - Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. *Med Toxicol* 1987;2:10-32.
 - Kobashigawa JA, Katznelson S, Laks H, et al. Impact of pravastatin on outcomes after cardiac transplantation. *N Engl J Med* 1995;333:621-627.
 - Korytkowski MT, Mokan M, Horwitz MJ, Berga SL. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 1995;80:3327-3334.
 - Kramer-Guth A, Quaschnig T, Greiber S, Wanner C. Potential role of lipids in the progression of diabetic nephropathy. *Clin Nephrol* 1996;46:262-265.
 - Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys (NHANES), 1960 to 1991. *JAMA* 1994;272:205-211.
 - Larsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. *Med Clin North Am* 1994;78:225-245.
 - Lea AP, McTavish D. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. *Drugs* 1997;53:828-847.
 - Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes. A 26-year follow-up of the Framingham population. *Am Heart J* 1986;113: 383-390.

- Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms. *N Engl J Med* 1995;332:512-519.
- Libby P. Molecular bases of the acute coronary syndromes. *Circulation* 1995; 91:2844-2850.
- Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) results. The reduction in incidence of coronary heart disease. *JAMA* 1984;251:351-364.
- Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. *JAMA* 1988;260:641-651.
- Manttari M, et al. Effect of gemfibrozil on the concentration and composition of serum lipoproteins: A controlled study with special reference to initial triglyceride levels. *Atherosclerosis* 1990;81:11-17.
- Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by healthcare providers. *Am J Med* 1996;100:605-610.
- Marcus AO. Diabetes Mellitus: Nephropathy and Hypertension. *Clinical Diabetes* 1996;July/August:91-94.
- Marcus AO. Rationale for effective treatment of hypercholesterolemia. *Am J Cardiol* 1996;78(Suppl 6A):4-12.
- Marcus, AO. Antihypertensive therapy with the calcium channel blocker isradipine: An appropriate choice for the diabetic patient with hypertension. *Curr Ther Res* 1993; 54:763-778.
- Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: Comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. *Clin Therapeutics* 1994;16: 1052-1062.
- Martens LL, Rutten FFH, Erkelens W, Ascoop CAPL. Clinical benefits and cost effectiveness of lowering serum cholesterol levels: The case of simvastatin and cholestyramine in The Netherlands. *Am J Cardiol* 1990;65 (Suppl):27F-32F.
- Martin MJ, Hulley SB, Browner WS, Hulley SB, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men. *Lancet* 1986;2:933-939.
- McKenney JM. Dyslipidemias. In: *Applied Therapeutics: The Clinical Use of Drugs*. 6th ed. Young LY, Koda-Kimble M, eds. Vancouver, WA: Applied Therapeutics Inc.; 1995.
- McKenney JM, Proctor JP, Harris S, et al. A dose response efficacy and safety evaluation of immediate release and sustained nicotinic acid in hypercholesterolemia patients. *JAMA* 1994;271:672-677.
- McVeigh GE. Arterial compliance in hypertension and diabetes mellitus. *Am J Nephrol* 1996;16:217-222.
- Meirow D, Raz I, Yossepowitch O, et al. Dyslipidemia in polycystic ovarian syndrome: Different groups, different etiologies. *Hum Reprod* 1996;11:1848-1853.
- Moller DE, Chang PY, Yaspelkis BB 3rd, Flier JS, Wallberg-Henriksson H, Ivy JL. Transgenic mice with muscle-specific insulin resistance develop increased adiposity, impaired glucose tolerance, and dyslipidemia. *Endocrinology* 1996;137:2397-2405.
- Muller C. Xanthomata, hypercholesterolemia, angina pectoris. *Acta Med Scand* 1938;89(Suppl):75-84.
- Multiple Risk Factor Intervention Trial (MRFIT) Research Group. Risk factor changes and mortality results. *JAMA* 1982;248:1465-1477.
- Nash DT. Meeting national cholesterol education goals in clinical practice—A comparison of lovastatin and fluvastatin in primary prevention. *Am J Cardiol* 1996;78 (Suppl 6A):26-31.
- National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). *Circulation* 1994;89:1329-1445.
- National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 1979;28:1039-1057.
- Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. *Arterioscler Thromb Vasc Biol* 1995;15:678-682.
- Neaton JD, Kuller LH, Wentworth D, Borhani NO. Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentrations, and diastolic blood pressure among black and white males followed up for five years. *Am Heart J* 1984;108:759-769.
- Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research (MRFIT) Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: Overall findings and differences by age for 316,099 white men. *Arch Intern Med* 1992;152:56-64.
- Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450C17X activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. *N Engl J Med* 1996;335:617-623.
- Nilsson P, Lundgren H, Soderstram M, Fägerstrom KO, Nilsson-Ehle P. Effects of smoking cessation on insulin

- and cardiovascular risk factors: A controlled study of four months' duration. *J Intern Med* 1996;240:189-194.
- Parving HH. Microalbuminuria in essential hypertension and diabetes mellitus. *J Hypertens Suppl* 1996;14:589-593.
 - Pearson TA, McBride PE, Houston-Miller N, Smith SC. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. *J Am Coll Cardiol* 1996;27:1039-1047.
 - Pedersen TR, Kjekshus J, Berg K, et al, for the Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;344:1383-1389.
 - Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: Results of the Scandinavian Simvastatin Survival Study. *Circulation* 1996;93:1796-1802.
 - Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. *N Engl J Med* 1990;322:1700-1707.
 - Polonsky KS, Sturis J, Bell GI. Non-insulin dependent diabetes mellitus: A genetically programmed failure of the beta-cell to compensate for insulin resistance. *N Engl J Med* 1996;331:777-783.
 - Post Coronary Artery Bypass Graft (Post-CABG) Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anti-coagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. *N Engl J Med* 1997;336:153-162.
 - Pyorala K, DeBacker G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society, and European Society of Hypertension. *Atherosclerosis* 1994;110:121-161.
 - Pyorala K, Pederson TR, Kjekshus J, et al, for The Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. *Diabetes Care* 1997;20:614-620.
 - Reaven GH, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. *N Engl J Med* 1996;334:374-381.
 - Reiber G, Pecoraro RE, Koepsell I. Risk factors for amputation in patients with diabetes mellitus. *Ann Int Med* 1992;117:97-105.
 - Robinson S, Henderson AD, Gelding SV, et al. Dyslipidemia is associated with insulin resistance in women with polycystic ovaries. *Clin Endocrinol* 1996;44:277-284.
 - Romm PA, Green CE, Reagan K, Rackley CE. Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease. *Am J Cardiol* 1991;67:479-483.
 - Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. *N Engl J Med* 1990;323:1112-1119.
 - Rossouw JE. The effects of lowering serum cholesterol on coronary heart disease risk. *Med Clin North Am* 1994;78:181-195.
 - Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *J Am Coll Cardiol* 1996;28:1328-1428.
 - Rytter L, Troelsen S, Nielsen HB. Prevalence and mortality of acute myocardial infarction in patients with diabetes mellitus. *Diabetes Care* 1985;8:230-234.
 - Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. The Harvard Atherosclerosis Reversibility Project (HARP) group: Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. *Lancet* 1994;344:1182-1186.
 - Sacks FM, Pfeffer MA, Moya LA, et al, for the Cholesterol and Recurrent Events (CARE) Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med* 1996;335:1001-1009.
 - Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1995;345:1274-1275.
 - Schmidt MI, Watson RL, Duncan BB, et al, for the Atherosclerosis Risk in Communities Study Investigators. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. *Metabolism* 1996;45:699-706.
 - Schulman KA, Kinoshian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: Cost effectiveness of pharmacologic management. *JAMA* 1990;264:2249-2254.
 - Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: *Hypertension*:

- Pathophysiology, Diagnosis, and Management*. 2nd ed. Laragh JH, Brenner BM, eds. New York, NY: Raven Press 1995;2861-2875.
- Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. *Diabetes* 1996;45:988-991.
 - Seidell JC, Verschuren WM, vanLeer EM, Kromhout D. Overweight, underweight, and mortality: A prospective study of 48,287 men and women. *Arch Intern Med* 1996;156:958-963.
 - Sempos CT, Cleeman JL, Carroll MD, et al. Prevalence of high blood cholesterol among US adults: An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. *JAMA* 1993;269:3009-3014.
 - Shamir R, Tershakovec AM, Gallagher PR, Liacouras CA, Hayman LL, Cortner JA. The influence of age and relative weight on the presentation of familial combined hyperlipidemia in childhood. *Atherosclerosis* 1996;121:85-91.
 - Shepherd J, Cobbe S, Ford I, et al, for the West of Scotland Coronary Prevention Study (WOSCOPS) Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med* 1995;333:1301-1307.
 - Shepherd J, Cobbe S, Ford I, et al, for the West of Scotland Coronary Prevention Study (WOSCOPS) Economic Analysis Group. The cost-effectiveness of preventing initial coronary events with pravastatin. Results of the West of Scotland Coronary Prevention Study Economic Analysis. *J Amer Coll Cardiol* 1997;29(Suppl A):Abstract #968-54 (168A).
 - Siskovick DS, Raghunathan TE, Psaty DM, et al. Diuretic therapy for hypertension and the risk of primary arrest. *N Engl J Med* 1994;330:1852-1857.
 - Slater EE, MacDonald JS. Mechanism of action and biological profile of HMG-CoA reductase inhibitors: A new therapeutic alternative. *Drugs* 1988;36(Suppl 3):72-82.
 - Smith SC, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. *Circulation* 1995;92:2-4.
 - Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. *Hypertension* 1995;26:869-879.
 - Stamler J, Vaccaro O, Neaton JD, Wentworth D, for The Multiple Risk Factor Intervention Trial (MRFIT) Research Group. Diabetes and other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 1993;16:434-444.
 - Stein EA. Drug and alternative therapies for hyperlipidemia. *Atherosclerosis* 1994;108(Suppl):S105-S116.
 - Talbert RL. Hyperlipidemia. In: *Pharmacotherapy: A Pathophysiologic Approach*. 3rd ed. JT Dipiro, RL Talbert, GC Yee, et al, eds. Stamford, CT: Appleton & Lange, 1997:459-489.
 - Tardiff JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. *N Engl J Med* 1997;337:365-372.
 - Tarnow L, Rossing P, Nielsen FS, Hansen BV, Dyerberg J, Parving HH. Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy. *Diabetes Care* 1996;19:1382-1387.
 - Thannhauser SJ, Magendantz H. The different clinical groups of xanthomatous disease: A clinical physiological study of 22 cases. *Ann Intern Med* 1938;11:1662-1746.
 - Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. *N Engl J Med* 1995;332:481-487.
 - Tsevat J, Duke D, Goldman L, Pfeffer MA. Cost-effectiveness of captopril therapy after myocardial infarction. *J Am Coll Cardiol* 1995;26:914-919.
 - Turner R, Cull C, Holman R, for the United Kingdom Prospective Diabetes Study (UKPDS) Group. United Kingdom Prospective Diabetes Study 17: A nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. *Ann Intern Med* 1996;124(Part 1):136-145.
 - US Department of Health and Human Services. Serum lipids of adults 20 - 40 years: United States, 1976-1980. *Vital Health Stat* 1993;11:22.
 - US Department of Health and Human Services. *Strategies to Control Tobacco Use in the United States: A Blueprint for Public Health Action in the 1990s*. US Department of Health and Human Services, 1991. (NIH Publication No. 92-3316.)
 - US Department of Health and Human Services. *The Health Consequences of Smoking: Nicotine Addiction—A report of the Surgeon General*. US Department of Health and Human Services, 1988. (CDC Publication No. 88-8406.)
 - Walton C, Lees B, Crook D, Worthington M, Godsland IF, Stevenson JS. Body fat distribution rather than overall adiposity influences serum lipids and lipoproteins in healthy men independent of age. *Am J Med* 1995;99:459-464.

... BIBLIOGRAPHY ...

- Waters D, Craven TE, Lespérance J. Prognostic significance of progression of coronary atherosclerosis. *Circulation* 1993;87:1067-1075.
- Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS) *Lancet* 1992;339:563-569.
- Wenger NK. Hypertension and other cardiovascular risk factors in women. *Am J Hypertens* 1995;(Part 8):945-995.
- Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia *Am J Med* 1993;94:13-20.
- Wilkin JK, Wilkin O, Kapp R, Donachie R, Chernosky ME, Buckner J. Aspirin blocks nicotinic acid-induced flushing. *Clin Pharmacol Ther* 1982;31:478-482.
- Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. *Circulation* 1990;81:1680.
- Wilson P, Cupples LA, Kannel W. Is hyperglycemia associated with cardiovascular disease? The Framingham Study *Am Heart J* 1991;121:586-590.
- Wittels EH, Hay JW, Gotto AM Jr. Medical costs of coronary artery disease in the United States. *Am J Cardiol* 1990;65:432-440.
- Wuerst JH Jr, Dry TJ, Edwards JE. The degree of coronary atherosclerosis in bilaterally oophorectomized women. *Circulation* 1954;7:801-809.
- Wurtman RJ, Wurtman JJ. Brain serotonin, carbohydrate-craving, obesity, and depression. *Obes Res* 1995;3(Suppl 4):4775-4805.
- Zarich SW, Nesto RW. Diabetic cardiomyopathy. *Am Heart J* 1989;188:1000-1011.
- Zavaroni I, Benora E, Pagliaria M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. *N Engl J Med* 1989;320:702-706.